HK
AKBA icon

Horizon Kinetics’s Akebia Therapeutics AKBA Stock Holding History

Horizon Kinetics’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$749K Buy
135,517
+83,841
+162% +$656K 0.02% 196
2018
Q3 		$456K Buy
+51,676
New +$462K 0.01% 281

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Horizon Kinetics's AKBA Position: Q4 2018 in Review

Horizon Kinetics increased its Akebia Therapeutics (AKBA) stake by 162% in Q4 2018, buying an estimated $656K and bringing the position to 135,517 shares worth $749K. The position accounts for 0.02% of the portfolio, ranked #196.

Horizon Kinetics first reported a position in AKBA in Q3 2018 and has held it in 2 quarters since. 166 funds tracked by Wall St. Rank hold AKBA as of Q4 2018.

  • Horizon Kinetics held 135,517 shares of Akebia Therapeutics worth $749K as of Q4 2018.
  • Horizon Kinetics bought 83,841 Akebia Therapeutics shares in Q4 2018, an estimated $656K.
  • Akebia Therapeutics made up 0.02% of Horizon Kinetics's portfolio in Q4 2018, its #196 holding.
  • Horizon Kinetics first reported a position in Akebia Therapeutics in Q3 2018 and has held it in 2 quarters since.
  • 166 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2018.

Based on Horizon Kinetics's 13F filing for Q4 2018, filed 14 Feb 2019.